Sintx Technologies SINT
Sintx Technologies reported record third quarter 2026 revenue growth.
Item 2.02 Reports results, Item 7.01 Investor disclosure
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001493152-26-050224
- Third quarter revenue increased to $2.2 million, up from $208,000 in the prior-year period.
- Net loss decreased 55% to $1.6 million compared to $3.5 million in the prior-year quarter.
- The company received $2.0 million in gross proceeds from the exercise of Class B warrants.
- Operating loss decreased 51% to $1.6 million compared to $3.4 million in the prior-year quarter.
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- The filing includes a press release with details on the Company's results of operations, financial condition, and revenue outlook.
- Item 2.02 of the Form 8-K covers Results of Operations and Financial Condition.
- It includes information on the Company's commercialization activities, customer purchase orders, product-development programs, and strategic initiatives.
- The Form 8-K also lists financial statements and exhibits, including the press release and an Interactive Data File.
- The filing was signed by Kevin Trask, the Chief Financial Officer, on November 5, 2026.
5 of 6 claims matched the filing text.
Not found in the filing text
- The information is part of the press release and is not deemed filed for liability purposes.
For perspective, checked against its own source
From the 10-Q for the quarter ended September 30, 2026
- In its 10-Q for the quarter ended September 30, 2026, Sintx Technologies, Inc. reported revenue of $2.2 million.
- The Company had a net income of -$1.6 million.
- Gross margin was 62.2%, and operating margin was -74.7%.
- These figures are from the Financial statements (XBRL) section of the 10-Q filing.
From the filing
Item 2.02 Results of Operations and Financial Condition.
Item
2.02 Results of Operations and Financial Condition2.
On
November 5, 2026, SINTX Technologies, Inc. (the "Company") issued a press release providing a business update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including certain information regarding the Company's results of operations, financial condition and revenue outlook. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
Item
7.01. Regulation FD Disclosure.
The information contained in the press release furnished as Exhibit 99.1 also includes updates regarding the Company's commercialization activities3, customer purchase orders, product-development programs, strategic initiatives and other business matters.
The information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
9.01 Financial Statements and Exhibits4.
Exhibit
No.
Description
99.1
Press Release dated November 5, 2026
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SINTX
Technologies, Inc.
Date:
November
5, 2026
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- OSR Health OSRH public float $8M, Dec 31, 2025
- Tenon Medical TNON public float $7M, Jun 30, 2025
- SeaStar Medical Holding ICU public float $7M, Jun 30, 2025
- ENvue Medical FEED public float $7M, Jun 30, 2025
- Bone Biologics BBLG public float $7M, Jun 30, 2025
